RxDoctor Payments DataLook up a doctor →

William Kaye, MD

Endocrinology, Diabetes & Metabolism · West Palm Beach, FLNPI 1003820002

Payments from drug & device makers

$1,311,428in general payments, 2019–2025

Across 2,492 payments — averaging $526.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$276K
  • Lilly USA, LLC$247K
  • Bayer$193K
  • Novo Nordisk$147K
  • Eli Lilly$119K
  • AbbVie$119K
  • plus $210K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS1,164$276,419
Lilly USA, LLC242$246,961
Bayer140$192,579
Novo Nordisk293$146,711
Eli Lilly5$119,466
AbbVie(2 entities)62$119,209
Boehringer Ingelheim105$78,392
AstraZeneca55$67,334
Abbott51$20,885
Merck23$17,541
Amarin Pharma, Inc.14$16,771
Amgen(2 entities)63$1,170
Tosoh Bioscience, Inc.2$1,078
Novartis19$950
Mannkind Corporation31$821
Sanofi-aventis U.S. LLC26$692
Insulet Corporation28$572
Xeris Pharmaceuticals, Inc.29$403
Dexcom, Inc.7$339
Antares Pharma, Inc.19$298
Sequel Med Tech, LLC6$259
Medtronic(2 entities)8$250
Tandem Diabetes Care, Inc.3$238
Neurocrine Biosciences, Inc.5$208
Amneal Pharmaceuticals LLC14$190
Radius Health, Inc.9$171
BETA Bionics, Inc.1$146
Ipsen Biopharmaceuticals, Inc3$144
Vivus LLC7$128
Madrigal Pharmaceuticals4$123
Corcept Therapeutics6$117
Lifescan, Inc.7$111
Alvogen Inc3$54
Halozyme Inc3$49
Ultragenyx Pharmaceutical Inc.2$48
Nevro Corp.2$45
Ascendis Pharma Endocrinology Inc2$43
Pfizer2$40
Verity Pharmaceuticals Inc.2$37
Sanofi Pasteur Inc.2$36
Takeda Pharmaceuticals U.S.A., Inc.2$34
Recordati_rare_diseases_inc.2$33
Quidel Corporation1$32
Globus Medical1$28
Acerus Pharmaceuticals Corporation2$27
Averitas Pharma Inc.1$24
Astellas Pharma US Inc1$22
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$21
Shire North American Group Inc1$21
Vanda Pharmaceuticals Inc.1$18
Kyowa Kirin, Inc.1$17
Alnylam Pharmaceuticals Inc.1$17
Tolmar, Inc.1$15
Vistapharm, Inc.1$15
Esperion Therapeutics, Inc.1$14
Amryt Pharma Holdings Ltd1$14
Companion Medical, Inc.1$13
Cardiovascular Systems Inc.1$12
Acella Pharmaceuticals, LLC1$11
Nalpropion Pharmaceuticals LLC1$11

How this compares

$1,311,428 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024
$908,923
Medicare patients
1,072
Services billed
35,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in West Palm Beach

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →